CellaVision AB (STU:C26)
€ 18.64 0.88 (4.95%) Market Cap: 454.18 Mil Enterprise Value: 445.31 Mil PE Ratio: 33.07 PB Ratio: 6.46 GF Score: 99/100

Q2 2020 CellaVision AB Earnings Call Transcript

Jul 16, 2020 / 09:00AM GMT
Release Date Price: €29.08 (+7.39%)
Operator

Ladies and gentlemen, welcome to the CellaVision AB Q2 report for 2020. Today, I'm pleased to present the CEO, Zlatko Rihter. (Operator Instructions) Mr. Rihter, please begin.

Zlatko Rihter;publ;President;CEO
CellaVision AB

()-&

Thank you very much, and welcome, everybody, to the quarter 2 report from CellaVision. With me today -- so I'm Zlatko Rihter, the CEO. I also have me Maria Morin, she's heading the HR and Corporate Communications for CellaVision; and Magnus Blixt, CFO. So we hope that we can address all types of questions that might pop up later.

But first of all, I will walk you through the numbers and also a little bit, of course, our strategy and so on as usual. And I suggest that we move to Slide #3. And of course, our vision, as before, is to be the global leader within digitalization, automatization of the blood analysis. We offer a method that really contributes to both improve diagnostics, but also efficiency in labs. And our primary target or call point at this time is the hematology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot